Key result
GLP-1 receptor agonists and their reported risk of non-arteritic anterior ischaemic optic neuropathy in patients with type 2 diabetes are the subject of critical methodological concerns.
Key points are not available for this paper at this time.
Answers are grounded in this paper and cite their sources.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Weng et al. (2025) studied this question. GLP-1 receptor agonists and their reported risk of non-arteritic anterior ischaemic optic neuropathy in patients with type 2 diabetes are the subject of critical methodological concerns.
Synapse has enriched 10 related papers. Consider them for comparative context: